Chapter 92 : Antibody and Biomarker Testing in Rheumatoid Arthritis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in

Antibody and Biomarker Testing in Rheumatoid Arthritis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH92-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH92-2.gif


Rheumatoid arthritis (RA) is a chronic systemic disease characterized by autoimmune-mediated joint destruction. RA affects 1% of the global population with a predilection for females. The pathogenesis of RA has not been fully elucidated; however, it is thought to be due to an environmental trigger stimulating an immune response in a genetically susceptible host. The resultant inflammatory cascade mediates synovial proliferation and ultimately joint destruction. Disease expression is not limited to the joints. Extra-articular manifestations occur in the lungs, eyes, skin, and the cardiovascular system culminating in significant morbidity and premature mortality (1). Moreover, numerous studies show substantial irreversible joint damage occurs within the first 2 years of disease onset. Thus, early diagnosis and aggressive treatment is paramount in preventing morbidity and mortality (2).

Citation: Chauffe A, Bubb M. 2016. Antibody and Biomarker Testing in Rheumatoid Arthritis, p 897-904. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch92
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Turesson C, Jacobsson L, Bergström U, Truedsson L, Sturfelt G. 2000. Predictors of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 29:358364.[PubMed].[CrossRef]
2. Hetland ML, Stengaard-Pedersen K, Junker P, Østergaard M, Ejbjerg BJ, Jacobsen S, Lottenburger T, Hansen I, Tarp U, Andersen LS, Svendsen A, Pedersen JK, Lauridsen UB, Ellingsen T, Lindegaard H, Pødenphant J, Vestergaard A, Jurik AG, Hørslev-Petersen K CIMESTRA Study Group. 2010. Radiographic progression and remission rates in early rheumatoid arthritis: MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 69:17891795.[CrossRef].[PubMed]
3. Silman AJ, Newman J, MacGregor AJ. 1996. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 39:732735.[PubMed].[CrossRef]
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:25692581.[CrossRef].[PubMed]
5. Cornec D, Varache S, Morvan J, Devauchelle-Pensec V, Berthelot JM, Le Henaff-Bourhis C, Hoang S, Martin A, Chalè G, Jousse-Joulin S, Saraux A. Comparison of ACR 1987 and ACR/EULAR 2010 criteria for predicting a 10-year diagnosis of rheumatoid arthritis. Joint Bone Spine 79:581585.
6. Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, Tanaka Y, Huizinga TW, Allaart CF. 2013. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 52:12021207.[CrossRef].[PubMed]
7. Natvig JB, Tønder O. 1998. The discovery of the rheumatoid factor. I. Erik Waaler. 1940. Clin Exp Rheumatol 16:340344.[PubMed]
8. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. 2002. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 41:809814.[PubMed].[CrossRef]
9. Pope RM, Lessard J, Nunnery E. 1986. Differential effects of therapeutic regimens on specific classes of rheumatoid factor. Ann Rheum Dis 45:183189.[PubMed].[CrossRef]
10. Shmerling RH, Delbanco TL. 1991. The rheumatoid factor: An analysis of clinical utility. Am J Med 91:528534.[PubMed].[CrossRef]
11. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson L EIRA Study Group. 2003. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 62:835841.[PubMed].[CrossRef]
12. Varache S, Cornec D, Morvan J, Devauchelle-Pensec V, Berthelot JM, Le Henaff-Bourhis C, Hoang S, Thorel JB, Martin A, Chalès G, Nowak E, Jousse-Joulin S, Youinou P, Saraux A. 2011. Diagnostic accuracy of ACR/EULAR 2010 criteria for rheumatoid arthritis in a 2-year cohort. J Rheumatol 38:12501257.[CrossRef].[PubMed]
13. Capra JD, Winchester RJ, Kunkel HG. 1969. Cold-reactive rheumatoid factors in infectious mononucleosis and other diseases. Arthritis Rheum 12:6773.[PubMed].[CrossRef]
14. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia MT, Zignego AL. 2003. HCV-related cryoglobulinemic vasculitis: An update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 21(Suppl 32):S78S84.[PubMed]
15. Roberts-Thomson PJ, McEvoy R, Langhans T, Bradley J. 1985. Routine quantification of rheumatoid factor by rate nephelometry. Ann Rheum Dis 44:379383.[PubMed].[CrossRef]
16. Demoruelle MK, Deane K. 2011. Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep 13:421430.[CrossRef].[PubMed]
17. Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR. 2009. Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential. Curr Opin Drug Discov Devel 12:616627.[PubMed]
18. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25:11061118.
19. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K. 2003. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395402.[CrossRef].[PubMed]
20. Avouac J, Gossec L, Dougados M. 2006. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review. Ann Rheum Dis 65:845851.[CrossRef].[PubMed]
21. Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, Serre G. 1995. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:26722679.[CrossRef].[PubMed]
22. dos Anjos LM, Pereira IA, d ‘Orsi E, Seaman AP, Burlingame RW, Morato EF. 2009. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:153158.[CrossRef].[PubMed]
23. Després N, Boire G, Lopez-Longo FJ, Ménard HA. 1994. The Sa system: A novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 21:10271033.[PubMed]
24. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Ménard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR Jr, El-Gabalawy HS. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236243.
25. Luime JJ, Colin EM, Hazes JM, Lubberts E. 2010. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69:337344.[CrossRef].[PubMed]
26. Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 76:248253.
27. Rubin B, Sønderstrup G. 2004. Citrullination of self-proteins and autoimmunity. Scand J Immunol 60:112120.[CrossRef].[PubMed]
28. Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K. 2004. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:10791084.[CrossRef].[PubMed]
29. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 50:380386.[CrossRef].[PubMed]
30. Schaller M, Burton DR, Ditzel HJ. 2001. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2:746753.[CrossRef].[PubMed]
31. Szomor Z, Shimizu K, Fujimori Y, Yamamoto S, Yamamuro T. 1995. Appearance of calpain correlates with arthritis and cartilage destruction in collagen induced arthritic knee joints of mice. Ann Rheum Dis 54:477483.[PubMed].[CrossRef]
32. Mimori T, Suganuma K, Tanami Y, Nojima T, Matsumura M, Fujii T, Yoshizawa T, Suzuki K, Akizuki M. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci U S A 92:72677271.
33. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen JS, Steiner G. 2005. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:17311736.[CrossRef].[PubMed]
34. Corrigall VM, Bodman-Smith MD, Brunst M, Cornell H, Panayi GS. 2004. Inhibition of antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an antiinflammatory cytokine profile by the stress protein BiP: relevance to the treatment of inflammatory arthritis. Arthritis Rheum 50:11641171.[CrossRef].[PubMed]
35. Rönnelid J, Lysholm J, Engström-Laurent A, Klareskog L, Heyman B. 1994. Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum 37:10231029.[PubMed].[CrossRef]
36. Atta MS, Lim KL, Ala'deen DA, Powell RJ, Todd I. 1995. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus. Ann Rheum Dis 54:117124.[PubMed].[CrossRef]
37. Mulder AH, Horst G, van Leeuwen MA, Limburg PC, Kallenberg CG. 1993. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations. Arthritis Rheum 36:10541060.[PubMed].[CrossRef]
38. Lee AN, Beck CE, Hall M. Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: A review. Clin Lab Sci 21:1518.
39. Houssien DA, Jónsson T, Davies E, Scott DL. 1998. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: comparative effects of different antigens. Scand J Rheumatol 27:4653.[PubMed].[CrossRef]
40. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. 1939. APMIS 115:422438; discussion 439.
41. Butler VP Jr, Vaughan JH. 1964. Hemagglutination by rheumatoid factor of cells coated with animal gamma globulins. Proc Soc Exp Biol Med 116:585593.[PubMed].[CrossRef]
42. Grunnet N, Espersen GT. 1988. Comparative studies on RF-IgA and RF-IgM ELISA—human or rabbit IgG as antigen? Scand J Rheumatol Suppl 75:3639.[PubMed].[CrossRef]
43. Taylor RN, Fulford KM, Jones WL. 1977. Reduction of variation in results of rheumatoid factor tests by use of a serum reference preparation. J Clin Microbiol 5:4245.[PubMed]
44. Anderson SG, Bentzon MW, Houba V, Krag P. 1970. International reference preparation of rheumatoid arthritis serum. Bull World Health Organ 42:311318.[PubMed]
45. Bizzaro N, Pregnolato F, van Boekel MA, Villalta D, Tozzoli R, Tonutti E, Antico A, Borghi MO, Wiik A, Meroni PL. 2012. Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. Ann Rheum Dis 71:13881392.[CrossRef].[PubMed]
46. Churchman SM, Geiler J, Parmar R, Horner EA, Church LD, Emery P, Buch MH, McDermott MF, Ponchel F. 2012. Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor. Clin Exp Rheumatol 30:534542.[PubMed]
47. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. 2012. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 64:17941803.[CrossRef].[PubMed]
48. Zhao X, Qureshi F, Eastman PS, Manning WC, Alexander C, Robinson WH, Hesterberg LK. 2012. Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis. J Immunol Methods 378:7280 10.1016/j.jim.2012.02.007.[CrossRef].[PubMed] http://dx.doi.org/10.1016/j.jim.2012.02.007
49. Borque L, Rus A, Ruiz R. Automated turbidimetry of rheumatoid factor without heat inactivation of serum. Eur J Clin Chem Clin Biochem 29:521527.
50. Virella G, Hipp WA, John JF Jr, Kahaleh B, Ford M, Fudenberg HH. 1979. Nephelometric detection of soluble immune complexes: methodology and clinical applications. Int Arch Allergy Appl Immunol 58:402410.[PubMed].[CrossRef]
51. Sasso EH. 2000. The rheumatoid factor response in the etiology of mixed cryoglobulins associated with hepatitis C virus infection. Ann Med Interne (Paris) 151:3040.[PubMed]
52. Gorgani NN, Altin JG, Parish CR. 1999. Histidine-rich glycoprotein prevents the formation of insoluble immune complexes by rheumatoid factor. Immunology 98:456463.[PubMed].[CrossRef]
53. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. 2000. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 235:7180.[PubMed].[CrossRef]
54. Benacerraf B. 1981. Role of MHC gene products in immune regulation. Science 212:12291238.[PubMed].[CrossRef]
55. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Dahlqvist SR. 2004. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:R303R308.[CrossRef].[PubMed]
56. van der Woude D, Lie BA, Lundström E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, Verduijn W, Nordang GB, Alfredsson L, Klareskog L, Pascual-Salcedo D, Gonzalez-Gay MA, Lopez-Nevot MA, Valero F, Roep BO, Huizinga TW, Kvien TK, Martín J, Padyukov L, de Vries RR, Toes RE. 2010. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: A meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 62:12361245.[CrossRef].[PubMed]
57. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A, Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, BIRAC Consortium Barton A, Bowes J, Brouwer E, Burtt NP, Catanese JJ, Coblyn J, Coenen MJ, Costenbader KH, Criswell LA, Crusius JB, Cui J, de Bakker PI, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Lee AT, Liu X, Martin P, Morgan AW, Padyukov L, Posthumus MD, Radstake TR, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, van der Schoot CE, van Riel PL, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth BP, YEAR Consortium Wijmenga C, Karlson EW, Toes RE, de Vries N, Begovich AB, Worthington J, Siminovitch KA, Gregersen PK, Klareskog L, Plenge RM. 2010. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508514.[CrossRef].[PubMed]
58. Silman AJ. 1997. Problems complicating the genetic epidemiology of rheumatoid arthritis. J Rheumatol 24:194196.[PubMed]
59. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. 2006. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:3846.[CrossRef].[PubMed]
60. Sahatçiu-Meka V, Rexhepi S, Kukeli A, Manxhuka-Kërliu S, Pallaskas K, Murtezani A, Rexhepi M, Rexhepi B. 2013. Course and prognosis in seropositive and seronegative rheumatoid arthritis. Reumatizam 60:1924.[PubMed]


Generic image for table

Summary of well-characterized autoantigens in rheumatoid arthritis

Citation: Chauffe A, Bubb M. 2016. Antibody and Biomarker Testing in Rheumatoid Arthritis, p 897-904. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch92
Generic image for table

Comparison of antibody assays

Citation: Chauffe A, Bubb M. 2016. Antibody and Biomarker Testing in Rheumatoid Arthritis, p 897-904. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch92

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error